News and Announcements
MedAdvisor International Pty Ltd (ASX:MDR) Annual Update 2015; Lists on the ASX & Establishes Important Partnerships
- Published January 05, 2016 2:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2015 Highlights:
- Raises $5m in oversubscribed public offer
- Commences trading on the ASX under ticker code MDR
- Announces new medication training relationship with Amgen
- Share price up 90% since listing
- Established important partnerships with pharmaceutical companies GSK, UCB, AstraZeneca and Apotex, as well as private health insurer, BUPA
- One quarter of Australian pharmacies subscribed to the MedAdvisor platform
ABOUT MEDADVISOR INTERNATIONAL:
MedAdvisor International Pty Ltd is an Australian medical technology business focused on designing and commercialising world class software platforms for medication management on mobile and internet devices. MedAdvisor’s Platform connects to pharmacy dispensing systems, automatically retrieving medication records and driving an intelligent training, information and reminder system to ensure correct and reliable medication use.
MedAdvisor has established strategic partnerships with Bupa Australia and most recently, distribution partner Apotex Australia. The company is also supported by Australia’s major pharmacies including Amcal, Chemmart, Terry White Chemists, Guardian Pharmacy and more.